Watch out, Bris­tol My­ers — J&J is right be­hind you; Blake By­ers leaps out from GV to do his own thing

We’ve learned that J&J has now fin­ished its rolling ap­pli­ca­tion for the BC­MA-tar­get­ed cil­ta-cel, which one an­a­lyst be­lieves will put them about 8 or 9 months be­hind Bris­tol My­ers Squibb and their part­ners at blue­bird, which just won a de­layed OK at the FDA for ide-cel.

Leg­end in­clud­ed word of the wrap-up dur­ing Q1 in its 20F fil­ing with the FDA, and an­a­lysts were quick to con­clude that should al­low for an ap­proval by the end of this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.